BioLineRx Initiates GLIX1 Glioblastoma Trial, Secures Key Patent, Extends Cash Runway
BLRX sits 16% above its 52-week low of $2.3.
Summary
BioLineRx announced significant progress, initiating a Phase 1/2a clinical trial for its lead asset GLIX1 in glioblastoma by the end of March. This is a critical first-in-human step for the development-stage company, targeting a high unmet need. Concurrently, the company secured a key U.S. patent for GLIX1, extending protection until 2040 and broadening its potential applications beyond glioblastoma. Financially, BioLineRx reported $20.9 million in cash as of December 31, 2025, maintaining its cash runway guidance into the first half of 2027, providing crucial stability for ongoing R&D. Additionally, enrollment has accelerated in the CheMo4METPANC Phase 2b trial for motixafortide, with an interim analysis expected in 2026. Traders will be watching for GLIX1 Phase 1 data in H1 2027 and the motixafortide interim analysis in 2026 as key upcoming catalysts.
At the time of this announcement, BLRX was trading at $2.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.6M. The 52-week trading range was $2.30 to $7.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.